INBX's two main pipeline candidates are entering critical late-stage trials with data readouts expected in mid- to late-2025. Click here to read my analysis.

Mesothelioma is an aggressive tumor with a poor prognosis. Histological diagnosis of mesothelioma using limited tissue samples can be challenging. Xia & He Publishing Inc.Oct 27 2024 Background and ...

Mesothelioma is an aggressive tumor with a poor prognosis. Histological diagnosis of mesothelioma using limited tissue samples can be challenging. Carbonic anhydrase IX (CAIX) is a transmembrane ...

According to Surveillance, Epidemiology and End Result (SEER) data from the National Cancer Institute, the incidence of malignant mesothelioma in 2008 was approximately 1 per 100,000 persons in ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved two new indications for KEYTRUDA ® (pembrolizumab), Merck ...

Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab in patients with PD-L1–positive advanced non–small cell lung cancer. Ivonescimab reduced the risk of ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 ...

BRIDGEPORT, Conn. — On Oct. 15, a jury determined that Johnson & Johnson must pay $15 million to local real-estate developer Evan Plotkin, who claims to have developed mesothelioma as a result of ...

Dr. Shannon Westin (Host), Dr. Brian Slomovitz (Guest) Dr. Shannon Westin and her guest, Dr. Brian Slomovitz discuss the article “Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without ...

HOUSTON, Oct. 15, 2024 /PRNewswire/ -- Mesothelioma, a rare but aggressive cancer caused by exposure to asbestos, affects thousands of individuals each year. For those diagnosed, the challenges ca ...